All In Biotech

Drug Trial Radar · NCT00746447

Once Daily (OD) Versus Three Times Daily (TID) Dosing With Mesalazine Granules for Prevention of Recurrence of Ulcerative Colitis (UC)

Double-blind, Double-dummy, Randomised, Multicentre, 12-months, Comparative Study of the Efficacy and Tolerability of Once Daily 3.0 g Mesalazine Granules vs. Once Daily 1.5 g Mesalazine Granules vs. Three Times Daily 0.5 g Mesalazine Granules for Maintenance of Remission in Patients With Ulcerative Colitis

Last checked: Nov 19, 2026Latest source record: Jun 26, 2012 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 648 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

648

Actual

Start

May 2005

Primary completion

Apr 2007

Study completion Mar 2008

Sponsor

Lead sponsor
Dr. Falk Pharma GmbHIndustry
Sponsor type
Industry
First posted
Sep 4, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study intends to study the efficacy and tolerability of once daily 3.0 g mesalazine granules vs. once daily 1.5 g mesalazine granules vs. three times daily 0.5 g mesalazine granules for maintenance of remission in patients with ulcerative colitis

Conditions

  • Colitis, Ulcerative
  • Recurrence

Interventions

  • mesalamine granulesDrug

    3.0g mesalamine in the morning, 0.5g placebo at lunch, 0.5g placebo in the evening;

  • mesalamine granulesDrug

    1.5g mesalamine and 1.5g placebo in the morning, 0.5g placebo at lunch, 0.5g placebo in the evening;

  • mesalamine granulesDrug

    0.5g mesalamine and 2.5g placebo in the morning, 0.5g mesalamine at lunch, 0.5g mesalamine in the evening

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of patients still in clinical remission at the final/withdrawal examination, with clinical relapse defined as a CAI >4 with an increase of ≥3 points from baseline.Time frame: week 52 or premature withdrawal

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Evangelisches Krankenhaus Kalk, Medical Dept.

    Cologne, Germany

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.